Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Wisconsin Comprehensive Memory Program |
---|---|
Information provided by: | National Institute on Aging (NIA) |
ClinicalTrials.gov Identifier: | NCT00751907 |
The purpose of this study is to evaluate the hypothesis that in middle-aged, asymptomatic, adult children of persons with Alzheimer's disease (AD), atorvastatin therapy will beneficially affect mechanisms thought to contribute to AD risk by improving blood flow in the brain, improving cerebral perfusion, increasing brain activity patterns, and improving blood vessel function.
Condition | Intervention | Phase |
---|---|---|
Alzheimer's Disease |
Drug: atorvastatin Drug: Placebo |
Phase II |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Efficacy Study |
Official Title: | Impact of Atorvastatin on Cerebral Perfusion and Endothelial Function |
Enrollment: | 16 |
Study Start Date: | June 2006 |
Study Completion Date: | April 2007 |
Primary Completion Date: | April 2007 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: atorvastatin
40mg daily for 4 months
|
2: Placebo Comparator |
Drug: Placebo
Matching placebo daily for 4 months
|
Treatment with cholesterol-lowering medications, specifically statins, is associated with up to a 73% reduction in the prevalence of AD, suggesting a potentially promising role for statins in the prevention of AD. In order to better understand the mechanisms through which statins may possibly modify blood AD risk, this study will evaluate whether administration of atorvastatin favorably alters blood flow in the brain (measured by magnetic resonance imaging (MRI)) and blood vessel function (measured by ultrasound).
Participants will be asked to attend 3 visits over the course of the 4-month study. At the initial visit, participants will complete a short questionnaire about their past medical history and medication history. At the baseline visit, participants will be randomized in a 1:1 ratio to receive atorvastatin 40 mg nightly vs. matching placebo. At baseline and follow-up visits, participants will provide an update on medical problems and medications, review any potential side effects, and have fasting blood tests collected for safety monitoring, including liver and muscle enzyme monitoring. In addition, all participants will have MRI and ultrasound measures collected.
Ages Eligible for Study: | 40 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
United States, Wisconsin | |
University of Wisconsin | |
Madison, Wisconsin, United States, 53705 |
Principal Investigator: | Cynthia M. Carlsson, MD, MS | University of Wisconsin School of Medicine and Public Health |
Responsible Party: | University of Wisconsin School of Medicine and Public Health ( Cynthia M. Carlsson, MD, MS ) |
Study ID Numbers: | IA0138 |
Study First Received: | September 10, 2008 |
Last Updated: | September 10, 2008 |
ClinicalTrials.gov Identifier: | NCT00751907 |
Health Authority: | United States: Institutional Review Board |
Cerebral blood flow |
Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders Alzheimer Disease Central Nervous System Diseases Neurodegenerative Diseases |
Brain Diseases Dementia Atorvastatin Cognition Disorders Delirium |
Antimetabolites Molecular Mechanisms of Pharmacological Action Therapeutic Uses Antilipemic Agents Nervous System Diseases |
Enzyme Inhibitors Anticholesteremic Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors Tauopathies Pharmacologic Actions |